Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 3 | Journal of Biology

Figure 3

From: CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo

Figure 3

Sensitivity of rat and human-derived CNS cells and human cancer cells to BCNU or cisplatin. Cells were treated with (a,c,e,g) cisplatin and (b,d,f,h) BCNU over a wide dose range (0.1–100 μM and 5–200 μM, respectively). Each experiment was carried out in quadruplicate and repeated multiple times in independent experiments. Data represents mean of survival ± SEM, normalized to control values. There are no concentrations of either drug for which tumor cell lines were more sensitive than the more sensitive neural progenitor cells and oligodendrocytes.

Back to article page